Alexandra Vladimirovna Semyanikhina
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Alexandra Vladimirovna Semyanikhina has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
- Alexander D. Lipatnikov
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences, 16/10, Miklukho-Maklaya Street, Moscow 117997, Russia
1 shared publication Alexander Dmitrievich Lipatnikov
State Research Center “Institute of Bioorganic Chemistry Named After Academicians M.M. Shemyakin and Yu.A. Ovchinnikov” of the Russian Academy of Sciences, Moscow, Russia
1 shared publication- Alexey Nokel
Semiotik LLC, Moscow, Russia
1 shared publication - Dmitrii Atiakshin
Scientific and Educational Resource Center for Innovative Technologies of Immunophenotyping, Digital Spatial Profiling and Ultrastructural Analysis, Patrice Lumumba Peoples’ Friendship University of Russia (RUDN University), 117198 Moscow, Russia
1 shared publication - Dmitry V. Rogozhin
Department of Pathology and Clinical Pathology, Pirogov Russian National Research Medical University, Moscow 117997, Russia
1 shared publication - Elena V. Ogorodnikova
Federal State Budgetary Institution “National Medical Research Center of Oncology Named After N.N. Blokhin” of the Ministry of Health of the Russian Federation, 23, Kashirskoe Shosse, Moscow 115522, Russia
1 shared publication
Latest Publications
- Open Access
- 13 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 800
The Level of Antibodies to Tumor-Associated Glycans in Gastric Cancer Patients Is Lower than in Healthy Donors and Reduces with Age
A key function of naturally occurring antibodies is to control pathologically altered cells, such as those with aberrant glycosylation. Age-related diminution in the pool of B cells producing these immunoglobulins is linked to impaired anti-tumor immunity. In this study, the levels of antibodies against tumor-associated carbohydrate antigens (TACAs)—common in gastric cancer (GC) and other malignancies—were analyzed in 235 treatment-naïve GC patients (stages I–IV) and 76 healthy donors using a printed glycan array (PGA). We found that anti-glycan IgM levels, but not IgG, reduced with age in both patients and donors. Crucially, IgM levels against most glycans were significantly lower in the GC cohort compared with healthy donors, a trend that remained after age adjustment. Furthermore, an immunohistochemical analysis revealed that human anti-GalNAcα (Tn) antibodies—a well-characterized TACA in gastrointestinal cancers—bound to tumor cells and exhibited perinuclear and membrane staining in non-tumor surface cells within the same organ. These data support the hypothesis that gastric cancer patients have reduced levels of anti-glycan IgMs, which are responsible for the early recognition of transformed cells. This specific immunodeficiency may contribute to a permissive environment for tumor development.
- 13 January 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (2) , 800
Open AccessThe Level of Antibodies to Tumor-Associated Glycans in Gastric Cancer Patients Is Lower than in Healthy Donors and Reduces with Age
A key function of naturally occurring antibodies is to control pathologically altered cells, such as those with aberrant glycosylation. Age-related diminution in the pool of B cells producing these immunoglobulins is linked to impaired anti-tumor immunity. In this study, the levels of antibodies against tumor-associated carbohydrate antigens (TACAs)—common in gastric cancer (GC) and other malignancies—were analyzed in 235 treatment-naïve GC patients (stages I–IV) and 76 healthy donors using a printed glycan array (PGA). We found that anti-glycan IgM levels, but not IgG, reduced with age in both patients and donors. Crucially, IgM levels against most glycans were significantly lower in the GC cohort compared with healthy donors, a trend that remained after age adjustment. Furthermore, an immunohistochemical analysis revealed that human anti-GalNAcα (Tn) antibodies—a well-characterized TACA in gastrointestinal cancers—bound to tumor cells and exhibited perinuclear and membrane staining in non-tumor surface cells within the same organ. These data support the hypothesis that gastric cancer patients have reduced levels of anti-glycan IgMs, which are responsible for the early recognition of transformed cells. This specific immunodeficiency may contribute to a permissive environment for tumor development.
- Open Access
- 17 November 2023
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 21 (3) , 1-5
Innate IgM antibodies to mannose in patients with gastric cancer
- 17 November 2023
- Published by China Anti-cancer Association in Cancer Biology & Medicine
- Vol. 21 (3) , 1-5
Open AccessInnate IgM antibodies to mannose in patients with gastric cancer
- Open Access
- 1 January 2019
- Published by Euroasian Scientific and Industrial Chamber, Ltd.
- Vol. 7 (3 2019)
MOLECULAR AND GENETIC FEATURES OF COLORECTALCANCER IN YOUNG PATIENTS
- 1 January 2019
- Published by Euroasian Scientific and Industrial Chamber, Ltd.
- Vol. 7 (3 2019)
Open AccessMOLECULAR AND GENETIC FEATURES OF COLORECTALCANCER IN YOUNG PATIENTS